Research progress on the relationship between mucin1 and immunotherapy of multiple myeloma / 白血病·淋巴瘤

ABSTRACT

Multiple myeloma (MM) is a malignant tumor of plasma cells that remains incurable.More attentions have been lately directed to the immunotherapy,which has proven benefits in eradicating minimal residual disease of MM,reducing relapse and improving patients' overall survival.Mucin 1 (MUC1) is a tumor associated antigen of MM,and has attracted increasing interest as a potential target for MM immunotherapy.In addition,MUC1-based vaccines have quickly entered human clinical trials,and some promising responses have been reported.Here,an up-to-date review of MUC1-based immunotherapy of MM is given.